Fexofenadine

Author:Prof. Dr. med. Peter Altmeyer

All authors of this article

Last updated on: 29.10.2020

Dieser Artikel auf Deutsch

Requires free registration (medical professionals only)

Please login to access all articles, images, and functions.

Our content is available exclusively to medical professionals. If you have already registered, please login. If you haven't, you can register for free (medical professionals only).


Requires free registration (medical professionals only)

Please complete your registration to access all articles and images.

To gain access, you must complete your registration. You either haven't confirmed your e-mail address or we still need proof that you are a member of the medical profession.

Finish your registration now

DefinitionThis section has been translated automatically.

H1 antagonist.

IndicationThis section has been translated automatically.

Symptomatic treatment of seasonal allergic rhinitis, symptomatic treatment of chronic idiopathic urticaria

Pregnancy/nursing periodThis section has been translated automatically.

Do not use during pregnancy or lactation (insufficient data available).

Dosage and method of useThis section has been translated automatically.

Adults and children > 12 years: 1 time / day 1 film sheet p.o.

Note! A high-dose therapy for chronic urticaria, as recommended for other antihistamines, cannot be recommended for fexofenadine because of possible cardiotoxic side effects.

Undesirable effectsThis section has been translated automatically.

  • Occasionally: headache, drowsiness, dizziness, nausea.
  • Rarely: fatigue, insomnia, nervousness, exanthema, urticaria, pruritus and other hypersensitivity reactions, e.g. Quincke's edema. Other symptoms may include chest tightness, shortness of breath, flushing, anaphylactoid reactions, tachycardia or bradycardia.

InteractionsThis section has been translated automatically.

Erythromycin, ketoconazole: 2-3-fold increase of the plasma level of fexofenadine. Antacids containing aluminium or magnesium hydroxide: reduced bioavailability of fexofenadine.

PreparationsThis section has been translated automatically.

Telfast, Telfast acute

Note(s)This section has been translated automatically.

  • Antacids containing aluminium or magnesium hydroxide should be taken at the earliest 2 hours after application.
  • Fexofenadine is the effective metabolite of the cardiotoxic terfenadine (terfenadine was withdrawn from the market in some countries due to cardiac side effects) and is the one responsible for histamine H1 receptor antagonism. The unfavourable effects on the electrophysiology of the heart are said to be due to the terfenadine parent substance, not to the antihistaminically active metabolite.

PatientinformationThis section has been translated automatically.

Remember! The medication can lead to an impairment of the ability to react (participation in road traffic, operation of machines)!

LiteratureThis section has been translated automatically.

  1. del Cuvillo A et al (2006) Comparative pharmacology of the H1 antihistamines. J Investig Allergol Clin Immunol 16: 3-12
  2. Borchard U (2003) New H1 antihistamines in comparison. Allergology 1: 23-32
  3. Lareb (2010) "Fexofenadine and bradycardia". Pharmaceutical telegram 41: 32

Authors

Last updated on: 29.10.2020

Author: Prof. Dr. med. Peter Altmeyer